Navigation Links
AquaStar Holdings, Inc.'s Client Receives U.S. Patent 7,708,944 for Portable Capillary Sensor Technology
Date:4/28/2011

SANTA ANA, Calif., April 28, 2011 /PRNewswire/ -- AquaStar Holdings, Inc. (Pink Sheets: RPPR) is pleased to announce that the United States Patent and Trademark Office has issued patent number 7,708,944 for the Ultra-Sensitive, Portable Capillary Sensor technology utilized by the Capwave Enzyme-Linked Immuno-Sorbent Assay (ELISA) platform.

The patent, entitled "Ultra-Sensitive, Portable Capillary Sensor" details research completed at the State University of New York Binghamton supported in part by grants from the United States Environmental Protection Agency and IEEC/National Science Foundation. The patent method is the essence of the rapid, sensitive, and portable Enzyme-Linked ImmunoSorbent Assay (ELISA) platform Capwave technology, which enables the user to quickly detect Bioweapons (anthrax, bacillus globigii), Biomarkers (cancer, stem cells), Toxins (E. coli and salmonella in foodborne illness), Contaminants and Diseases (both viral and bacterial).

"We are very pleased with the progress being made toward the commercial offering of the Capwave technology. Obviously, gaining protection for the intellectual property is an important step in the process," stated Malcolm Lennie, President of AquaStar Holdings, Inc.

In further news, the Company recently announced that its client's Capwave licensed technology has received over $600,000 in federal research grants from the U.S. Government. The State University of New York (SUNY) Binghamton has confirmed that the U.S. Army Research Office, the U.S. Army Research Development & Engineering Command, the EPA and the National Research Council have contributed over $618,000 in total funding to benefit the Research and Development of Capwave's portable Enzyme-Linked Immuno-Sorbent Assay (ELISA) platform technology.

For more information on SUTIMCo, its portfolio companies, and University partners, please visit; http://www.suti.com

About AquaStar Holdings, Inc.:

AquaStar Holdings, Inc. is a holding company, which utilizes a unique and established platform to launch new technology enterprises based on world-class university research discoveries. AquaStar Holdings, through its wholly owned subsidiary SUTIMCo, Inc., provides experienced management to early stage companies, reducing risk and assuring the know-how in launching and growing a new company. In addition to this skilled management team, AquaStar Holdings can avail itself of the encyclopedic, informal knowledge of the inventor, his experience and his research team.

Safe Harbor: Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the safe harbors created thereby. The Company is a development stage company who continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results

Investor Relations
407-389-5900


'/>"/>
SOURCE AquaStar Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pacific Shore Holdings, Inc. Receives Symbol Change Approval From FINRA
2. Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
3. China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic
4. China Pharma Holdings, Inc. CEO to Speak at Brean Murray, Carret & Co. 2010 Life Sciences Summit
5. China Pharma Holdings, Inc. Reports First Quarter 2010 Financial Results
6. VirtualHealth Technologies Will Change Its Name to VHGI Holdings, Inc. and Surges Forward Into Broader Market
7. China Pharma Holdings, Inc. to Present at Brean Murray China Growth Conference
8. Applied Technology Holdings, Inc. Announces Board of Directors
9. China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates
10. Cellu Tissue Holdings, Inc. Files Registration Statement for Proposed Initial Public Offering of Common Stock
11. China Pharma Holdings, Inc. to Present at the Roth China Conference on October 14 at 12:00 pm ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2017)...  Trianni, Inc. („TRIANNI") gab heute bekannt, man ... über die Verwendung der The Trianni Mouse unterschrieben, ... Entdeckung monoklonaler Antikörper. Die Trianni Plattform ... das Janssen den Zugang zu einer ... für die schelle Isolierung vollständig menschlicher Therapeutika optimiert ...
(Date:2/15/2017)... 2017  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), ... fourth quarter and full year ended December 31, ... for Vanda as we continued to demonstrate strong ... exclusivity for Fanapt," said Mihael H. Polymeropoulos, M.D., ... pipeline with important 2017 milestones underscores Vanda,s commitment ...
(Date:2/15/2017)... Feb. 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, will ... presentation) at 8:00 AM EST on Thursday, February 16, ... clinical program, the recently announced closing of a $10.5 ... To participate in the live call and ...
(Date:2/15/2017)... ... February 15, 2017 , ... Diameter Health ... Diameter Health technology in the hands of Lantana analysts. The high-performance platform of ... and public health entities – all those mining value from clinical data – ...
Breaking Biology Technology:
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
Breaking Biology News(10 mins):